About GliMR
The Action
Core Leadership
Management Committee
Participants
Stakeholders
Working Groups
WG1 – Advanced MRI biomarkers for glioma characterisation
WG2 – Multi-site data integration
WG3 – Clinical translation
WG4 – Stakeholder relations
WG5 – Dissemination
News
Grants
Short Term Scientific Mission (STSM)
STSM Calls
STSM Awardees
ITC Conference Grants
ITC Conference Grant Calls
ITC Conference Grant Awardees
Events
Output
Output
Newsletters
Publications
Contacts
Twitter Instagram
Menu
About GliMR
The Action
Core Leadership
Management Committee
Participants
Stakeholders
Working Groups
WG1 – Advanced MRI biomarkers for glioma characterisation
WG2 – Multi-site data integration
WG3 – Clinical translation
WG4 – Stakeholder relations
WG5 – Dissemination
News
Grants
Short Term Scientific Mission (STSM)
STSM Calls
STSM Awardees
ITC Conference Grants
ITC Conference Grant Calls
ITC Conference Grant Awardees
Events
Output
Output
Newsletters
Publications
Contacts
Menu
About GliMR
The Action
Core Leadership
Management Committee
Participants
Stakeholders
Working Groups
WG1 – Advanced MRI biomarkers for glioma characterisation
WG2 – Multi-site data integration
WG3 – Clinical translation
WG4 – Stakeholder relations
WG5 – Dissemination
News
Grants
Short Term Scientific Mission (STSM)
STSM Calls
STSM Awardees
ITC Conference Grants
ITC Conference Grant Calls
ITC Conference Grant Awardees
Events
Output
Output
Newsletters
Publications
Contacts

Core Leadership

The Action
Core Leadership
Management Committee
Participants
Stakeholders
Home
/
/
Core Leadership
Esther Warnert
Esther Warnert
e.warnert@erasmusmc.nl
MC Chair
Erasmus MC - University Medical Centre, Rotterdam
Netherlands
Radim Jancalek
Radim Jancalek
radim.jancalek@fnusa.cz
MC Vice-Chair
Masaryk University, Brno & St. Anne's University Hospital Brno
Czech Republic
Lydiane Hirschler
Lydiane Hirschler
l.hirschler@lumc.nl
WG1 Leader
Leiden University Medical Center
Netherlands
Kyrre Emblem
Kyrre Emblem
kyrre.eeg.emblem@rr-research.no
WG1 Vice-Leader
Oslo University Hospital
Norway
Camille Maumet
Camille Maumet
camille.maumet@inria.fr
WG2 Leader
Inria, Univ Rennes, CNRS, Inserm
France
Cyril Pernet
Cyril Pernet
cyril.pernet@ed.ac.uk
WG2 Vice-Leader
University of Edinburgh
United Kingdom
Jan Petr
Jan Petr
j.petr@hzdr.de
WG3 Leader
Helmholtz-Zentrum Dresden-Rossendorf
Germany
Vera C Keil
Vera C Keil
v.c.w.keil@amsterdamumc.nl
WG3 Vice-Leader
Amsterdam University Medical Center
Germany
Marion Smits
Marion Smits
marion.smits@erasmusmc.nl
WG4 Leader
‘Erasmus MC - University Medical Centre, Rotterdam
Netherlands
Fran Borovecki
Fran Borovecki
fbor@mef.hr
WG4 Vice-Leader
University of Zagreb
Croatia
Patricia Clement
Patricia Clement
patricia.clement@ugent.be
WG5 Leader & Science Communication Officer
Ghent Institute for Functional and Metabolic Imaging (GIfMI)
Belgium
Joana Pinto
Joana Pinto
joana.pinto@eng.ox.ac.uk
WG5 Vice-Leader; MC Substitute
Institute of Biomedical Engineering, Department of Engineering Science, University of Oxford
United Kingdom
Ruben Nechifor
Ruben Nechifor
rubennechifor@psychology.ro
STSM Coordinator
Babes-Bolyai University, Cluj-Napoca
Romania
Patrícia Figueiredo
Patrícia Figueiredo
patricia.figueiredo@tecnico.ulisboa.pt
ITC Conference Grant Coordinator
Instituto Superior Técnico, Universidade de Lisboa
Portugal
Follow Us
Twitter Instagram Linkedin

COST

COST (European Cooperation in Science and Technology) is a funding agency for research and innovation networks. Our Actions help connect research initiatives across Europe and enable scientists to grow their ideas by sharing them with their peers. This boosts their research, career and innovation.
www.cost.eu

COST Action CA18206

This COST Action aims to build a pan-European and multidisciplinary network of international experts in glioma research, patient organisations, data scientists, and MR imaging scientists by uniting the glioma imaging community within Europe and progressing the development and application of advanced MR imaging for improved decision making in diagnosis, patient monitoring, and assessment of treatment response in clinical trials and clinical practice.
COST CA18206 Website

Action Details

Memorandum of Understanding (MoU)
Start Date: 12 September 2019
End Date: 11 September 2023
CSO approval date: 4 June 2019
Email: glimrca18206@erasmusmc.nl

Subscribe Newsletter

By subscribing you agree with our Privacy Policy.
© 2020 GliMR2.0 COST Action CA18206   •   Privacy Policy
Design by Boutik